Indication
Primitive Neuroectodermal Tumor
5 clinical trials
5 products
4 drugs
Clinical trial
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH MedulloblastomaStatus: Completed, Estimated PCD: 2022-09-30
Drug
GemcitabineClinical trial
Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Recruiting, Estimated PCD: 2026-05-01
Product
SCRI-CARB7H3Drug
ribociclibProduct
sonidegibDrug
trametinibDrug
FilgrastimClinical trial
Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-26
Clinical trial
Phase 1 Study of EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-01
Product
Zoledronate